Clinical Trial Update: 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Lutetium-177 DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• LUTATHERA (Lutetium Lu-177 dotatate)

Snippet

Sponsor: Jakob Stenman | Conditions: Neuroblastoma Recurrent, Neuroblastoma | Phase 2 | Status: RECRUITING